HJ-217
/ HJ Science
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2025
A novel, highly selective and potent FGFR4 inhibitor HJ-217 for the treatment of liver cancer [WITHDRAWN]
(AACR 2025)
- "Our study indicates that HJ-217 is a highly selective FGFR4 inhibitor with encouraging antitumor activity, which may provide an effective treatment for HCC patients."
Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • FGF19 • FGFR1 • FGFR4
1 to 1
Of
1
Go to page
1